Administration, Intravesical
Urinary Bladder
BCG Vaccine
Carcinoma, Transitional Cell
Cystitis
Cystitis, Interstitial
Propantheline
Urinary Bladder, Neurogenic
Mitomycin
Ureter
Urinary Bladder, Overactive
Cystotomy
Mycobacterium bovis
Tuberculosis, Cardiovascular
Urinary Bladder Neck Obstruction
Neoplasm Recurrence, Local
Dose-Response Relationship, Drug
Drug Administration Schedule
Rats, Sprague-Dawley
Ureteral Neoplasms
Immunotherapy
Antibiotics, Antineoplastic
Tuberculosis, Male Genital
Reflex, Abnormal
Carcinoma in Situ
Disease Models, Animal
Urethra
Treatment Outcome
Urologic Surgical Procedures
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Prostatism
United States Food and Drug Administration
Urination Disorders
Reflex
Rats, Wistar
Neuromuscular Agents
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
Drug Administration Routes
Hyperthermia, Induced
Botulinum Toxins, Type A
Hypogastric Plexus
Aneurysm, Infected
Dogs
Parasympatholytics
Urine
Mitomycins
Pressure
Urinary Bladder Calculi
Mucous Membrane
An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.
Combined Modality Therapy
Urinary Tract
Injections, Intraperitoneal
Vesico-Ureteral Reflux
Muscle Contraction
Pelvis
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. (1/242)
We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25). (+info)Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. (2/242)
We report a case of Mycobacterium bovis BCG vertebral osteomyelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer. The recovered isolate resembled M. tuberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect. High-pressure liquid chromatographic studies confirmed the diagnosis of M. bovis BCG infection. The patient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambutol, and PZA. When susceptibility studies were reported, the regimen was changed to isoniazid and rifampin for 12 months. Subsequently, the patient was transferred to a skilled nursing facility for 3 months, where he underwent intensive physical therapy. Although extravesical adverse reactions are rare, clinicians and clinical microbiologists need to be aware of the possibility of disseminated infection by M. bovis BCG in the appropriate setting of clinical history, physical examination, and laboratory investigation. (+info)Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. (3/242)
More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups of 2; n = 6) received 100 mg, 350 mg, or 1 g of drug by intravesical administration on alternate days three times/week for 4 weeks. Animals were observed for clinical signs of toxicity; gemcitabine levels and peripheral blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy was performed at days 1 and 14 after the last dose. Intravesical gemcitabine was given at 100 mg (n = 2), 350 mg (equivalent to the 1000 mg/m2 human dose; n = 3), and 3.5 g (n = 1). i.v. gemcitabine was given at 350 mg (n = 2). Plasma samples drawn at time points up to 8 h were analyzed for systemic absorption and clearance of drug. Doses of 100 and 350 mg were well tolerated with no clinical side effects. Necropsies revealed normal bone marrow cellularity and normal bladder histology. At 1 g, signs of severe clinical toxicity were evident, and after only three doses, necropsies demonstrated severe bone marrow hypoplasia, cystitis, and intestinal necrosis. At all intravesical doses, significant systemic absorption was seen. The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001). Intravesical gemcitabine is well tolerated and has no direct bladder toxicity at doses up to 1000 mg/m2. Higher doses result in gastrointestinal, bladder, and bone marrow toxicity. (+info)Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. (4/242)
Although Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effective agent in clinical use against superficial bladder cancer, its mechanism of action remains incompletely understood. A kinetic analysis in assessing the potential role of cytokines from BCG-stimulated murine splenocytes showed that IL-12 expression preceded that of other cytokines. Experiments subtracting endogenous BCG-driven IL-12 using neutralizing Ab or augmenting its activity with supplemental rIL-12 revealed not only that IL-12 plays a dominant role in IFN-gamma induction but also that it is normally dose limiting. A striking increase in IFN-gamma production could be generated in both mouse and human immunocompetent cell culture by the addition of even a small amount of rIL-12. Moreover, this same synergistic effect could be replicated during in vivo administration of BCG plus rIL-12 into the mouse bladder and was observed in a patient receiving intravesical combination therapy. In costimulation cultures, this synergy appeared to partially rely on IL-18 and IL-2 and could be down-regulated by IL-10. This suggests that a dynamic interplay between Th1 and Th2 cytokines is responsible for net IFN-gamma production. The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy. (+info)Primary lymphoma of the bladder treated successfully with mitozantrone gel. (5/242)
We describe a young man who presented with a short history of painless haematuria. Subsequent investigations and biopsy of lesions found in his bladder at cystoscopy confirmed the diagnosis of primary lymphoma of the bladder. Computed tomography studies confirmed the disease was localised to his bladder. Unfortunately, the tumour was not eradicated by radiotherapy. However, it was successfully treated with intravesical mitozantrone given in a novel gel formation. Three years after diagnosis the patient remains well with no evidence of recurrence. (+info)Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. (6/242)
PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 ((67)Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy. PATIENTS AND METHODS: Approximately 20 MBq of (67)Cu-C595 monoclonal antibody was administered intravesically to 16 patients with a clinical indication of superficial bladder cancer. After 1 hour, the bladder was drained and irrigated. Tissue uptake was assessed by imaging and by the assay of tumor and normal tissues obtained by endoscopic resection. RESULTS: Tumor was correctly identified in the images of 12 of 15 patients who were subsequently found to have tumors. Assay of biopsy samples at 2 hours showed a mean tumor uptake of 59.4% of the injected dose per kilogram (SD = 48.0), with a tumor-to-normal tissue ratio of 14.6:1 (SD = 20). After 24 hours (n = 5), this decreased to 4.3% of the injected dose per kilogram (SD = 2.9), with a tumor-to-normal tissue ratio of 1.8:1 (SD = 0.8). CONCLUSION: This study indicates a promising method for the treatment of superficial bladder cancer. Although the mean initial tumor uptake was high, effective therapy of bladder tumors will require an increased retention of the cytotoxic radionuclide in tumor tissue. (+info)Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. (7/242)
Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5x10(5) MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. Beta-Galactosidase (beta-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with beta-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer. (+info)Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. (8/242)
The local immune response to mycobacteria is complex, but mycobacterial antigen presentation by phagocytes to T helper cells is the pivotal interaction. Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Animal studies have shown that an intact host immune system is required for the antitumor activity of BCG. Immunosuppressed and, particularly, T cell-depleted individuals fail to respond to BCG immunotherapy. Clinical and laboratory evidence suggest that the antitumor activity is concentrated at the site of BCG administration, which reinforces the view that local immune mechanisms are responsible for this phenomenon. (+info)A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of...
The effect of mitomycin C on superficial bladder cancer<...
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
Altmetric - Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for...
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder...
Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) - Full Text View -...
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel...
Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive...
Best Intravesical Chemotherapy Doctor in Delhi NCR, Intravesical Chemotherapy Doctors | Credihealth
Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study
SIU 2019: Changing the Paradigm in Intravesical Therapy for NMIBC
Enhanced urothelial ATP release and contraction following intravesical by Stanley Kang, Catherine M. McDermott et al.
Plus it
Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non...
Background This study aimed to judge the behavior of non-muscle-invasive bladder - Engineering a Therapeutic Lectin by...
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle...
Sequential BCG and electromotive mitomycin versus BCG alone for high- risk superficial bladder cancer: a randomised controlled...
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer...
Intravesical Therapy for Bladder Cancer
Bay Urology, Tauranga : Managing all Urological Conditions : Intravesical BCG Treatment
Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder<...
Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A...
A RARE COMPLICATION OF BCG IMMUNOTHERAPY | CBU International Conference Proceedings
Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical...
Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction...
Diagnosis and management of superficial bladder cancer<...
Bladder Cancer - Clinical Pain Advisor
Immuno-Oncology | The MD Anderson Manual of Medical Oncology, 3e | AccessHemOnc | McGraw-Hill Medical
MP08-11: Switching of bacillus Calmette-Guérin (BCG) stra ... ide effects in patients with BCG-relapsing tumor | AUA University
Carcinoma in Situ | Profiles RNS
Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. -...
Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with...
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following...
ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat,...
Kirkby Malzeard & Masham Surgeries - Library - Health A-Z
Plus it
Role of IL-12 in the Induction and Potentiation of IFN-γ in Response to Bacillus Calmette-Guérin | The Journal of Immunology
Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer | Clinical Cancer Research
The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer...
Optical diagnostics in urology: current applications and future prospects - Crow - 2003 - BJU International - Wiley Online...
Sodium hyaluronate & Sodium chondroitin sulphate bladder instillation - Lancashire and South Cumbria Medicines Management Group
Plus it
The Promise of Immune Checkpoint Blockade in Cancer Therapy - The ASCO Post
Universal Pharmacy: Viagra patong thailand best ED treatment
Most recent papers with the keyword Oxygen delivery | Read by QxMD
Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer<...
Bladder Cancer | DASPITE
Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case...
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer | Clinical Research Trial Listing (...
Global Intravesical Bacillus Calmette Market Research Report 2017
Table 1 | Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin ...
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a...
MP08-04: Purified protein derivative skin test prio ... ts with non-muscle invasive bladder cancer (APL - 2018) | AUA University
Mitomycin instillation medac - Slimming tea mustika ratu
Influences of Different Operative Methods on the Recurrence Rate of Non-Muscle-Invasive Bladder Cancer
| Urology Journal...
Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive...
Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial...
G9a Inhibition Has Antitumor Activity in Bladder Cancer | Cancer Discovery
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment | Protocol (Translated to Spanish)
Supplementary Material for: Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle...
Intravesical hyaluronic acid - effective option in the treatment of hemorrhagic cystitis | Instylan
Basic Concepts in Bladder Cancer Immunotherapy | Gotoper.com
Autophagy and urothelial carcinoma of the bladder: A review<...
Browse In pH (blood), Hyperkalaemia | EDM Case Reports
Intravesical therapy | Jeremy Ockrim - Consultant Urological Surgeon
Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs | Clinical Cancer Research
April 2015 ~ Valley OBGYN
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder - CareAcross
Mitomycin C - Wikipedia
Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus...
Bladder Cancer
Paper Alert 7 | Bladder Cancer
Plus it
Main Drugstore: Viagra not working first time express pills!
Trust Pharmacy: Levitra dose response graph best price guaranteed!
Private Drugstore: Buspar dosing no prescription brand store!
Multiple bladder biopsies under intravesical lignocaine anaesthesia. - PubMed - NCBI
Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated...
Applications filed at Jun 08 2017 | CANNULA STABILIZATION DEVICE | Patents.com
Protocols and Video Articles Authored by Muthiah Manoharan (Translated to Korean)
Ketamine
Intravesical botulinum toxin is also useful. Liver toxicity of ketamine involves higher doses and repeated administration. In a ... March 2017). "Administration of ketamine for unipolar and bipolar depression". International Journal of Psychiatry in Clinical ... However, the antidepressant action of a single administration of ketamine wanes with time. The long-term effects of repeated ... In February 2022, the US Food and Drug Administration issued an alert to health care professionals concerning compounded nasal ...
Route of administration
Intravesical infusion is into the urinary bladder. Intravitreal, through the eye. Subcutaneous (under the skin). This generally ... Oral administration is often denoted "PO" from "per os", the Latin for "by mouth". The bioavailability of oral administration ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ... Extra-amniotic administration, between the endometrium and fetal membranes. Nasal administration (through the nose) can be used ...
Mucoadhesion
Intravesical drug administration is the delivery of pharmaceuticals to the urinary bladder through a catheter. This route of ... Consequently, direct administration through the fibrous tunic is common. This is made difficult due to the numerous defense ... With a 0.1-0.7 mm thick mucus layer, the oral cavity serves as an important route of administration for mucoadhesive dosages. ... With an active surface area of 160 cm2, the nasal cavity is another noteworthy route of mucoadhesive administration. Due to the ...
Bladder cancer
Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ... TURBT with intravesical therapy is indicated after treatment failure for non-muscle invasive disease. In people with solitary ... Salvage therapy include intravesical chemotherapy with agents such as valrubicin, gemcitabine or docetaxel, chemoradiation or ... The induction course consists of 6-week course of intravesical and percutaneous BCG. This is followed by a maintenance course. ...
Tumor-homing bacteria
BCG therapy is done by intravesical instillation (drug administration into the urinary bladder via a catheter) and has been ... "Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma". ...
Thiotepa
In 1959, thiotepa was registered with the Food and Drug Administration (FDA) as a drug therapy for several solid cancers. On ... Thiotepa is used as intravesical chemotherapy in bladder cancer. It may be used prophylactically to prevent seeding of tumor ... "Urgent, Thiotepa update" (PDF). U.S. Food and Drug Administration (FDA). 5 April 2011. Retrieved 25 November 2011. Maanen MJ, ... "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa". Postgraduate Medical Journal. 58 (680 ...
List of MeSH codes (E05)
... administration, intravaginal MeSH E05.300.120.505 - administration, intravesical MeSH E05.300.120.610 - administration, rectal ... administration, buccal MeSH E05.300.100.878 - administration, sublingual MeSH E05.300.120.040 - administration, buccal MeSH ... E05.300.120.060 - administration, cutaneous MeSH E05.300.120.080 - administration, intranasal MeSH E05.300.120.500 - ...
Apaziquone
After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were ... October 2006). "Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer". J. Urol. 176 (4 Pt 1 ... The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to apaziquone for this indication. "UvA ...
Valrubicin
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory ... Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008 "Endo Pharmaceuticals launches VALSTAR for treating ...
Treatment of cancer
The Veterans administration and an adjuvant trial found that there were no evidence to support racial differences in treating ... Contemporary methods for generating an immune response against tumours include intravesical BCG immunotherapy for superficial ... In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. Although the ... Other problems include route of administration, maintenance of stability and activity and targeting at the tumor vasculature. ...
Sodium hyaluronate
"Filling in Wrinkles Safely". U.S. Food and Drug Administration. 2016-12-20. Wickens JM, Alsaab HO, Kesharwani P, Bhise K, Amin ... "Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress ... "Soft Tissue Fillers Approved by the Center for Devices and Radiological Health". U.S. Food and Drug Administration. 2015-07-27 ...
Transurethral resection of the prostate syndrome
... reduces the intra-vesical pressure required to initiate absorption, and therefore increases the risk of irrigation fluid ... Concurrently the slow administration of intravenous diuretics such as furosemide can correct the sodium by diuresis, however ...
Robot-assisted surgery
Food and Drug Administration. 39 (4): 16-7. PMID 16252396. Archived from the original on 1 March 2009. McConnell PI, ... Ureteral reimplantation - alternative to the open intravesical or extravesical surgery. Ureteroureterostomy - alternative to ...
Prokar Dasgupta
Sahai, Arun; Kalsi, Vinay; Khan, Mohammad S.; Fowler, Clare J. (2006). "Techniques for the intradetrusor administration of ... Dasgupta, Prokar (2000). Towards an understanding of the role of intravesical capsaicin in the treatment of detrusor ... "A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable ...
Tata Memorial Centre
... and the role of urinary cytokines in intravesical BCG therapy in superficial bladder cancer. The biology of HIV-2, the virus ... Government of India which also oversees the administration of institute since 1962. The Tata Memorial Hospital was initially ...
Interstitial cystitis
... intravesical bacillus Calmette Guerin, intravesical resiniferatoxin), high-pressure and long-duration hydrodistention, and ... "Policy Interpretation Ruling Titles II and XVI: Evaluation of Interstitial Cystitis". Social Security Administration. Archived ... Tyagi P, Kashyap MP, Kawamorita N, Yoshizawa T, Chancellor M, Yoshimura N (January 2014). "Intravesical liposome and antisense ...
Thiomer
In case of oral administration this 'enzymatic barrier' is even more pronounced as an additional degradation caused by ... "Development of pre-activated α-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery". Int. J. Pharm. 534 (1 ... Madgulkar, AR; Bhalekar, MR; Kadam, AA (2017). "Improvement of oral bioavailability of lopinavir without co-administration of ...
Oncolytic virus
It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck ... "Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus ...
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder...
Mitomycin / administration & dosage* * Urinary Bladder Neoplasms / drug therapy * Urinary Bladder Neoplasms / therapy* ... The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder ... One option is chemohyperthermia (C-HT): microwave-induced hyperthermia (HT) with intravesical chemotherapy, typically mitomycin ...
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients - Full...
Study Drug and PDT Administration. TLD-1433 for intravesical administration is supplied as a lyophilisate for suspension in ... Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients. The ... Prior treatment with an intravesical chemotherapeutic agent within 1 month of the first dose of current Study Drug, with the ... Up to 24 hours before administration, it is reconstituted with Sterile Water for Injection to obtain the final clinical ...
Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Overview of BCG Immunotherapy, Mechanism of Action of BCG,...
... is a live attenuated strain of Mycobacterium bovis and is the only agent approved by the US Food and Drug Administration as the ... In an Intermediate-risk patient, a clinician should consider administration of a 6-week course of induction intravesical ... a clinician should consider administration of a single postoperative instillation of intravesical chemotherapy (eg, gemcitabine ... Intravesical Administration of Therapeutic Medication. AUA. Available at https://www.suna.org/sites/default/files/download/ ...
Electrically stimulated chemotherapy for non muscle invasive bladder cancer | Cancer Research UK
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.. J H Jung and others. The Cochrane ... Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer [IPG638]. National Institute for ... Applications of electromotive drug administration in urology. S Hashemi and others. Urology Annals, 2020 Volume 12, Issue 4, ... The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive ...
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC | NYU Langone Health
Display 25 results per page
Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration. Urology ... To compare the outcomes of intravesical injection of botulinum toxin A (BoNTA) with intravesical electromotive drug ... administration (EMDA) of BoNTA on urinary incontinence secondary to neuropathic detrusor overactivity (NDO) in children with ...
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | Clinical Research Trial Listing...
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer ... or one administration of systemic therapy for NMIBC treatment. Yes for In the previous 12 months, received at least one ... No for In the previous 12 months, received at least one instillation of any intravesical agent (induction or maintenance) or ... instillation of any intravesical agent (induction or maintenance) or one administration of systemic therapy for NMIBC treatment ...
Valrubicin Intravesical: MedlinePlus Drug Information
BCG Vaccine (Tice strain) (BCG vaccine live) dosing, indications, interactions, adverse effects, and more
Intravesical administration may cause symptoms of bladder irritability 4-6 hr after instillation and increase in severity ... Intravesical administration may cause disseminated infections. Contains live attenuated mycobacteria (handle with care and ... Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines ... Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines ...
Mitomycin - Drug Info, Side Effects, Research, Clinical Trials
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, ... of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive ... OFF Label USE (40), Incorrect Route of Drug Administration (24), Hepatic Failure (20), Hepatic Cirrhosis (10), Diarrhoea (8), ... Patients in the intravesical adjuvant electromotive and passive diffusion mitomycin groups who are disease-free 3 months after ...
CJU - Article Abstract: Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIP
Our findings support the continued need to explore ways of improving rates of perioperative IVC administration following TURBT ... Underutilization of immediate intravesical chemotherapy following TURBT: results from NSQIP Kowalik Casey, Gee R. Jason, ... We then identified those patients who underwent TURBT and also received intravesical therapy. Operative time, length of ... A single perioperative dose of intravesical chemotherapy (IVC) following transurethral resection of bladder tumors (TURBT) for ...
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical...
UGN-101 is delivered to patients using standard intravesical catheters.. The U.S. Food and Drug Administration has granted both ... Food and Drug Administration," said Ron Bentsur, Chief Executive Officer of UroGen. "This interim analysis also demonstrates ... also known as mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several ...
Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis...
AUA 2022: A Report From the Trenches
Interstitial Cystitis Clinical Presentation: History, Physical Examination
Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L. Intravesical liposome administration--a novel treatment for ... Guo C, Yang B, Gu W, Peng B, Xia S, Yang F. Intravesical resiniferatoxin for the treatment of storage lower urinary tract ... Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009 Oct. ... Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to ...
Serial Assessment of Circulating T lymphocyte Phenotype and Receptor Repertoire During Treatment of Non-Muscle Invasive Bladder...
We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were ... Background: Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are frequent despite intravesical therapy ... 2E, the unique TCR clones and the shared TCR clones changed after the administration of ACT. Moreover, as shown in Fig. 2F, the ... We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were ...
Publications - Institute for Bioengineering of Catalonia
Titles list | Archive ouverte UNIGE
Search Results
Gene Therapy Market (5th Edition) | Industry Analysis | Market Size | 2035
Routes of Administration. 3.5. Mechanism of Action. 3.6. Overview of Gene Editing. 3.6.1. Evolution of Genome Editing. 3.6.2. ... Intravesical, Intravitreal, Subretinal, Topical and Others), and Key Geographical Regions (US, Europe, Asia-Pacific and rest of ... 6.2.7. Analysis by Route of Administration. 6.3. Gene Therapy Market: Early-Stage Pipeline. 6.3.1. Analysis by Phase of ... 6.3.6. Analysis by Route of Administration. 6.4. Gene Therapy Market: Special Drug Designations. 6.4.1. Analysis by Special ...
Vol. 2: Issue 6
These options include transdermal or intravesical administration of antimuscarinics, intravesical administration of other ... along with transdermal or intravesical administration of antimuscarinics, intravesical administration of other agents ( ... However, neither vanilloid nor botulinum toxin therapy is approved by the United States Food and Drug Administration for ... TIVS sedation was achieved by intravenous administration of fentanyl (0.5-2 μg/kg), midazolam (0.03-0.05 mg/kg) and propofol ( ...
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2022) - American Urological Association
Damiano R, Quarto G, Bava I et al: Prevention of recurrent urinary tract infections by intravesical administration of ... Intravesical Hyaluronic Acid/Chondroitin. Two small, medium risk of bias trials evaluated intravesical hyaluronic acid plus ... than intravesical saline.200 Intravesical hyaluronic acid was also associated with better scores on the SF-36 (78.6 versus 53.1 ... Long-term administration of TMP-SMX appears to be safe, though hematologic and laboratory monitoring may be indicated. ...
Ultrasound | Bracco
Cytokines in clinical cancer immunotherapy | British Journal of Cancer
However, the systemic administration of this cytokine at the recommended dose is hampered by its toxic profile, which includes ... 57 It has also been reported that ALT-803 is well tolerated in combination with intravesical bacillus Calmette-Guérin therapy ... The systemic administration of cytokines requires optimisation of the pharmacokinetic profile to increase the half-life in ... Administration of the PEGylated cytokine (termed pegilodecakin) is well tolerated, and grade 3-4 immune-related adverse effects ...
Find Research outputs
- Yonsei University
Clinical Trials - Mayo Clinic Research
The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue ... The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue ... The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to ... CISTO, The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study (CISTO) ...
Instillation4
- In a patient with suspected or known low- or intermediate-risk bladder cancer, a clinician should consider administration of a single postoperative instillation of intravesical chemotherapy (eg, gemcitabine, mitomycin C) within 24 hours of a transurethral resection for bladder tumor (TURBT). (medscape.com)
- BACKGROUND: The clinical effect of intravesical instillation of chemotherapy immediately after transurethral resection of bladder tumours (TURBT) has recently been questioned, despite its recommendation in guidelines. (druglib.com)
- The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. (bvsalud.org)
- Panel members also addressed the magnitude of response that would be clinically meaningful for various disease strata and trial design options for perioperative intravesical chemotherapy instillation at the time of resection of bladder tumors. (elsevier.com)
Electromotive drug administration1
- Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer. (druglib.com)
Immunotherapy3
- High-grade NMIBC is treated initially with endoscopic resection and intravesical immunotherapy, followed by bladder instillations of BCG. (centerwatch.com)
- We hypothesized that administration of an activated T cell immunotherapy (ACT) at times when immunosuppressive populations were noted to have increased in peripheral blood would prevent recurrence of disease. (researchsquare.com)
- In this report, we describe a patient with multiple lesions of resected NMIBC, devoid of expression of PD-1 or PD-L1 who received standard intravesical treatment and intravenous chemotherapy followed by DC-CIK immunotherapy for 18 cycles over 63 months. (researchsquare.com)
Bacillus2
- The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscule invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease. (mayo.edu)
- Production during intravesical bacillus calmette-gurin treatment with administration of aspirin lower rates of mon causes of upper urinary atively. (mylifestyle.us)
Transurethral resection of bladder1
- A single perioperative dose of intravesical chemotherapy (IVC) following transurethral resection of bladder tumors (TURBT) for non-muscle invasive bladder cancer has demonstrated a reduction in tumor recurrence. (canjurol.com)
Mitomycin3
- One option is chemohyperthermia (C-HT): microwave-induced hyperthermia (HT) with intravesical chemotherapy, typically mitomycin C (MMC). (nih.gov)
- Mitomycin for Injection is a sterile dry mixture of mitomycin and mannitol, which when reconstituted with Sterile Water for Injection provides a solution for intravenous administration. (druglib.com)
- moreover, it reduces recurrence rates and enhances the disease-free interval compared with intravesical PD mitomycin after TURBT and TURBT alone. (druglib.com)
Gemcitabine1
- A031803 Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (A031803) Scottsdale/Phoenix, Ariz. (mayo.edu)
TURBT3
- We then identified those patients who underwent TURBT and also received intravesical therapy. (canjurol.com)
- Our findings support the continued need to explore ways of improving rates of perioperative IVC administration following TURBT. (canjurol.com)
- 12. History of prior treatment with an intravesical chemotherapeutic agent in the past 2 years except for a single dose of chemotherapy immediately after any previous TURBT. (mountsinai.org)
Therapy4
- In an intermediate- or high-risk patient with persistent or recurrent disease or positive cytology following intravesical therapy, consider performing prostatic urethral biopsy and an upper tract evaluation prior to administering additional intravesical therapy (conditional recommendation, evidence strength, grade C). (medscape.com)
- The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. (centerwatch.com)
- Recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are frequent despite intravesical therapy. (researchsquare.com)
- Administration of radiation therapy for bladder cancer is done through linear accelerators that produce high-energy external radiation beams such that it penetrates the tissues and deliver the radiation dose into deeper areas. (careshareplus.com)
Injection5
- TLD-1433 for intravesical administration is supplied as a lyophilisate for suspension in Sterile Water for Injection into the bladder and is packaged in the dark in amber USP Type III glass vials which can be stored at room temperature. (clinicaltrials.gov)
- Up to 24 hours before administration, it is reconstituted with Sterile Water for Injection to obtain the final clinical dilution. (clinicaltrials.gov)
- Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe, or by the insertion of an indwelling catheter. (mental-health-matters.org)
- Intracerebral (into the cerebrum) administration by direct injection into the brain. (mental-health-matters.org)
- L'agrégation plaquettaire induite par le collagène dans des échantillons de plasma riche en plaquettes de 14 lapins sains a été mesurée par turbidimétrie en utilisant un agrégomètre, avant et une heure après une injection intra- veineuse d'alun. (who.int)
Topical3
- An exception is topical administration, which generally means that both the application location and the effect thereof is local. (mental-health-matters.org)
- Topical administration is sometimes defined as both a local application location and local pharmacodynamic effect, and sometimes merely as a local application location regardless of location of the effects. (mental-health-matters.org)
- Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local (sometimes termed topical), such as in a contrast enema, whereby contrast media are infused into the intestines for imaging. (mental-health-matters.org)
Patients1
- Ces résultats semblent indiquer que l'utilisation de l'alun en tant qu'antiplaquettaire oral pourrait faire l'objet d'études complémentaires, en tenant compte des effets secondaires éventuels notamment chez les patients dont la fonction rénale est altérée. (who.int)
Treatment8
- Conservative measures and oral or intravesical treatments are considered first-line treatment. (medscape.com)
- Only two cytokines, IL-2 and IFN-α, demonstrated mild clinical benefit and consequently received The Food and Drug Administration (FDA) approval for the treatment of several malignant diseases. (nature.com)
- A planning process and simulation before treatment of bladder cancer with radiotherapy helps make careful measurements to find exact angles for administration and the right dosage. (careshareplus.com)
- 9. Evidence of active urinary tract infection (UTI) that in the Investigator's opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment. (mountsinai.org)
- Radical cystectomy (complete removal of the bladder) is used for treatment of extensive multiple superficial cancers or CIS unresponsive to intravesical therapies. (cancerconnect.com)
- BCG treatment for high risk non-invasive bladder cancer is the most effective intravesical treatment for bladder cancer. (dralexurology.com)
- However, the antidepressant action of a single administration of ketamine wanes with time, and also the consequences of repeated use (beyond the 6 suggested ketamine for treatment resistant depression sessions) have not been satisfactorily learned (if any). (reconsciousmedical.com)
- The current thinking is that 6-12 weeks after initiating treatment with traditional antidepressant(s), both dendritic growth and increased esophageal connections occur, but with ketamine, that can happen within 24 hours of their administration. (reconsciousmedical.com)
MeSH1
- Administration, Intravaginal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
Clinical1
- In this pilot telemetric study, bladder function was not affected by oral administration of urological drugs at their recommended clinical dosages. (biomedcentral.com)
Administer1
- 4. Administer or teach self-administration of intravesical chemotherapy and on overcoming barriers that interfere with optimal bulk of the resection. (berea.edu)
Oral3
- The use of oral antimuscarinic agents as a first-line approach is discussed, along with transdermal or intravesical administration of antimuscarinics, intravesical administration of other agents (including vanilloids and botulinum toxins A and B), and electrical stimulation. (urotoday.com)
- Common examples include oral and intravenous administration. (mental-health-matters.org)
- Enteral/enteric administration usually includes oral (through the mouth) and rectal (into the rectum) administration, in the sense that these are taken up by the intestines. (mental-health-matters.org)
Prostatic urethra1
- Animal Toxicology And/Or Pharmacology In a study to evaluate inadvertent peribladder administration, bladder stones were observed in 1 of 4 mal e monkeys that were injected with a total of 6.8 Units/kg divided into the prostatic urethra and proximal rectum (single administration). (clustermed.info)
NMIBC1
- Objective To summarize the discussion at a public workshop, cosponsored by the U.S. Food and Drug Administration (FDA) and the American Urological Association, reviewing potential trial designs for the development of new therapies for non-muscle-invasive bladder cancer (NMIBC). (elsevier.com)
Drug4
- A route of administration in pharmacology and toxicology is the way by which a drug, fluid, poison, or other substance is taken into the body. (mental-health-matters.org)
- Route of administration and dosage form are aspects of drug delivery . (mental-health-matters.org)
- The Food and Drug Administration (FDA) believes that the recommendations in this guidance document will improve the quality of postmarketing safety reports and clarify the industry's current safety reporting responsibility to assure public health. (cdc.gov)
- 1This guidance has been prepared by the Epidemiology Branch in the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. (cdc.gov)
Tract2
- A standard imaging test has been an X-ray examination with intravesical administration of an iodine contrast agent for assessment of the excretory urinary tract. (bracco.com)
- However, uptake of drugs administered orally may also occur already in the stomach, and as such gastrointestinal (along the gastrointestinal tract) may be a more fitting term for this route of administration. (mental-health-matters.org)
Rectum1
- In hospice care, a specialised rectal catheter, designed to provide comfortable and discreet administration of ongoing medications provides a practical way to deliver and retain liquid formulations in the distal rectum, giving health practitioners a way to leverage the established benefits of rectal administration. (mental-health-matters.org)
Dosage1
- A suppository is a solid dosage form that fits for rectal administration. (mental-health-matters.org)
Effective1
- The rectal route is an effective route of administration for many medications, especially those used at the end of life. (mental-health-matters.org)
Infusion1
- Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. (medscape.com)
Hours1
- In contrast, ketamine-mediated synaptic plasticity changes appear to occur within a matter of hours immediately after ketamine administration. (reconsciousmedical.com)
Days1
- Electromyographic urethral activity was significantly increased 8 days after oestriol or duloxetine administration. (biomedcentral.com)
Route of administrat1
- What is Route of Administration? (mental-health-matters.org)
Drugs1
- Urethral smooth muscle electrical activity appears to be modified by administration of drugs with urethral tropism. (biomedcentral.com)
Safe1
- Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. (who.int)